

Supplementary Table S1. Clinical and metabolic data evaluated in the four groups of subjects.

Parameter	A - Diabetics with CHD (n=33)	B – Diabetics without CHD (n=31)	C - Non-diabetics with CHD (n=30)	D – Controls (n=27)
Age (y)	65.5±8.3 ^a	60.0±5.9 ^a	65.6±6.0 ^a	47.3±13.4 ^b
BMI (kg/m ²)	29.8±3.9 ^a	29.2±3.4 ^{ab}	26.8±5.1 ^{bc}	25.5±3.3 ^c
FPG (mg/dl)	142±41 ^a	144±36 ^a	91±11 ^b	89±14 ^b
HbA1c (%)	7.0±0.8 ^a	6.9 ±0.8 ^a	5.8±0.2 ^b	5.5±0.4 ^b
Total cholesterol (mg/dl)	151±35 ^b	191±35 ^a	155±40 ^b	194±19 ^a
LDL cholesterol (mg/dl)	82±30 ^b	112±39 ^a	86±31 ^b	116±18 ^a
HDL cholesterol (mg/dl)	42±9 ^b	49±10 ^{ab}	53±16 ^a	56±13 ^a
Triglycerides (mg/dl)	161±80 ^a	138±72 ^a	91±40 ^b	93±28 ^b

BMI, body mass index; CHD, coronary heart disease; FPG, fasting plasma glucose; GLY-HSA, glycated albumin; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein. Data are expressed as mean ±SD. For each variable, means of groups not sharing any superscript letter are significantly different by the Tukey's HSD test at the 5% level of significance.

Supplementary Table S2. Significant correlations between the metabolic and glyco-oxidation parameters evaluated considering all the patients (groups A, B and C; n=94).

Parameter correlation	Pearson's <i>r</i>	<i>p</i>
AGE vs FPG	0.2955	0.0042
AGE vs HbA1c	0.2781	0.0073
AGE vs Pentosidine	0.2427	0.0198
AGE vs RAGE	0.3795	0.0002
RAGE vs sRAGE	0.5928	<0.0001
GLY-HSA vs FPG	0.3738	0.0002
GLY-HSA vs HbA1c	0.4903	<0.0001
GLY-HSA vs THIO-HSA	-0.3505	0.0005
THIO-HSA vs FPG	-0.3685	0.0003
THIO-HSA vs HbA1c	-0.3753	0.0002
THIO-HSA vs AGE [†]	0.3805	0.0289

AGE, advanced glycation end products; FPG, fasting plasma glucose; GLY-HSA, glycated albumin; HbA1c, glycated hemoglobin; RAGE, receptor for advanced glycation end-products; sRAGE, soluble RAGE; THIO-HSA, thiolated albumin. [†]The correlation THIO-HSA vs AGE is referred to Group A (Diabetics with CHD) only; no significant correlation was found for groups B and C.